On April 15, 2025 Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported it will host a virtual key opinion leader (KOL) event featuring Zev A. Wainberg, MD, Professor of Medicine at University of California, Los Angeles (UCLA) and co-director of the UCLA GI Oncology Program, on Wednesday, April 23, 2025 at 2:30 p.m. ET (Press release, Leap Therapeutics, APR 15, 2025, View Source [SID1234651948]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Wainberg will connect with Leap’s Chief Medical Officer, Cynthia Sirard, MD, to discuss the unmet need and how sirexatamab (DKN-01) may improve upon the current treatment landscape for previously treated patients with advanced microsatellite stable (MSS) colorectal cancer (CRC).
The event will focus on reviewing the positive data from Part B of the Phase 2 DeFianCe study of sirexatamab in second-line patients with advanced MSS CRC. Sirexatamab, Leap’s most advanced clinical program, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein.
A live Q&A will follow the discussion. A replay of the event will be available for a limited time on the Investors page of the Company’s website at View Source
About Zev A. Wainberg, MD
Zev A. Wainberg, MD, is the Professor of Medicine at UCLA and co-director of the UCLA GI Oncology Program. He was trained in medical oncology and hematology at UCLA. He completed his residency training at Albert Einstein College of Medicine and received his MD from the Sackler School of Medicine, New York Program at Tel Aviv University. His research involves a variety of clinical trials in multiple gastrointestinal cancers including pancreas, colon, gastric, and esophageal. Dr. Wainberg’s laboratory-based research efforts involve the testing of novel therapeutics against all gastrointestinal cancers. Currently, he is the recipient of several grants focused on the targeting of cancer stem cells and in molecular classification of gastrointestinal cancers.